144876-59-5

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 4507-57-7 methyl 1-aminocyclohexanecarboxylate 
• 75-44-5 phosgene 
• 37993-32-1 1-amino-cyclohexanecarboxylic acid methyl ester hydrochloride 
• 503-38-8 trichloromethyl chloroformate 
• 2756-85-6 1-aminocyclohexane carboxylic acid 

Downstream Products

• 144876-71-1 phenylmethyl -4-(1H-indol-3-ylmethyl)-1-<1-(methoxycarbonyl)cyclohexyl>-2,5-dioxo-8-phenyl-1,3,6,9-tetraazadecan-10-oate 
• 144876-72-2 phenylmethyl -4-(1H-indol-3-ylmethyl)-1-<1-(methoxycarbonyl)cyclohexyl>-4-methyl-2,5-dioxo-8-phenyl-1,3,6,9-tetraazadecan-10-oate 
• 864805-00-5 C₃₀H₄₇N₅O₇ 
• 1044501-13-4 methyl 1-({[(4-chloro-2-fluorophenyl)amino]carbonyl}amino)cyclohexanecarboxylate 
• 1044501-17-8 methyl 1-({[(4-chloro-3-fluorophenyl)amino]carbonyl}amino)cyclohexanecarboxylate 
• 144876-96-0 <10R-(10α,14β,17α)>-10-(1H-indol-3-ylmethyl)-10-methyl-8,11,16,19-tetraoxo-14-phenyl-7,9,12,15,18-pentaazaspiro<5,13>nonadecane-17-acetic acid 
• 144876-96-0 <10R-(10α,14α,17α)>-10-(1H-indol-3-ylmethyl)-10-methyl-8,11,16,19-tetraoxo-14-phenyl-7,9,12,15,18-pentaazaspiro<5,13>nonadecane-17-acetic acid 
• 144876-85-7 4-methyl-1-(phenylmethyl) -N-<<1-<<<<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<<2-phenyl-2-<<(phenylmethoxy)carbonyl>amino>ethyl>amino>ethyl>amino>carbonyl>amino>cyclohexyl>carbonyl>-L-aspartate 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease

Norovirus infections have a major impact on public health worldwide, yet there is a current dearth of norovirus-specific therapeutics and prophylactics. This report describes the discovery of a novel class of macrocyclic inhibitors of norovirus 3C-like pr

Toward the back-up of Boceprevir (SCH 503034): Discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles

Hepatitis C is the most prevalent liver disease. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically an estimated 300 million people worldwide. Results of Phase I clinical studies with our first generation HCV inhibitor Boceprevir, SCH 503034 (1), presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) were encouraging, and thus, additional human clinical studies are underway. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P4 pocket and optimization of the P1′ capping led to the discovery of new ketoamide inhibitors of the HCV NS3 serine protease with improved in vitro potency. In addition to being potent inhibitors of HCV subgenomic RNA replication, some of the new P4-capped inhibitors were also found to have improved PK profile.

GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS

Compounds of Formula (I) or a salt thereof are provided: wherein R6, R7, R8, R21, X, Ar, and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further discloses pharmaceutical compositions and combinations comprising the compounds.

Synthesis and CCK-B Binding Affinities of Cyclic Analogues of the Potent and Selective CCK-B Receptor Antagonist CI-988

A selected series of 14-membered macrocyclic compounds (2) has been prepared as potential CCK-B receptor selective ligands.The efficiency of a number of cyclising reagents has also been evaluated.